Research-grade compound. Laboratory use only. Not intended for human or animal use, ingestion, or injection. No medical claims are made or implied.
BPC-157 + TB-500 Blend
This report covers the 10mg lot. Other sizes ship to our supplier batch specification.
3–7 days most of the EU · 8–14 Nordics/Baltics
Standard EU from €4.99 (RO) · core EU GLS €17.99 · Nordics/Baltics €12.99–€13.99 · Same-day dispatch before 14:00 CET on weekdays · Free shipping over €200 · no customs paperwork (EU) · via EU carrier network
€200.00 away from free shipping over €200. Under that, standard EU shipping is €17.99 (GLS, most of the EU).
How Paysera and SEPA work
- Pay — approve a SEPA transfer in your own bank via Paysera’s hosted page, or send a manual SEPA transfer using the IBAN we email you.
- We confirm — Paysera notifies us instantly, or we match a manual transfer when it arrives (usually 1 business day).
- We dispatch — confirmed orders placed before 14:00 CET on a weekday typically ship the same day.
Card payments are not currently offered. There is no card processor on this checkout.
Free shipping on orders over €200
Synergistic blend combining BPC-157 (VEGFR2/NO/FAK pathways) and TB-500 (actin regulation/progenitor cell mobilization) for multi-pathway tissue repair research. ≥98% supplier batch specification per component; selected lots independently tested. For laboratory research use only.
| Quantity | Price Each | Total | Savings |
|---|---|---|---|
| 1 unit | €71.99 | €71.99 | -- |
| 3+ | €68.39 | €205.17 | 5% off |
| 5+Most Popular | €64.79 | €323.96 | 10% off |
| 10+ | €61.19 | €611.92 | 15% off |
Important Notice
This product is intended for laboratory and research use only. Not for human or veterinary use. By purchasing, you confirm this product will be used exclusively for in-vitro research purposes.
Reconstitution Required
This peptide ships lyophilized (dry powder) and requires bacteriostatic water to reconstitute before use. BAC water is sold separately.
When This Product May Not Suit Your Research
- ⚠If your research requires GMP-grade material for clinical applications — research-grade peptides are not intended for clinical use.
- ⚠If your lab lacks proper cold storage (-20°C freezer) — this peptide's stability may be compromised at higher temperatures.
- ⚠If your study protocol requires FDA-approved reference standards — contact USP or a certified reference material provider.
Published laboratory reports are available for selected lots. Check each report for its result and stated method. For research purposes only.
This report covers the 10mg lot. Other sizes ship to our supplier batch specification.
24h dispatch, EU-wide shipping from €4.99
Supplier batch specification on every product; independent Janoshik report on selected lots
About BPC-157 + TB-500 Blend
BPC-157 + TB-500 is a blend combining two of the most widely researched tissue repair peptides. BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide with documented stability in gastric conditions and well-replicated effects on GI mucosal protection, tendon healing, and nitric oxide pathway modulation. TB-500 is the 17-amino acid LKKTET-containing fragment of thymosin beta-4, responsible for actin cytoskeleton regulation, cell migration, and anti-inflammatory signaling. Each vial contains 5mg BPC-157 and 5mg TB-500 (10mg total).
The rationale for combining them is mechanistic complementarity. BPC-157 primarily modulates the nitric oxide system, promotes angiogenesis through VEGFR2 signaling, and protects mucosal surfaces. TB-500 acts through actin dynamics and cell migration -- it promotes the cell movement needed for tissue remodeling and repair. Both have been studied in overlapping contexts (fibroblast proliferation in cited models, tendon repair, muscle injury), but through different enough mechanisms that combination research is scientifically justified. Some published studies have examined co-administration and found additive effects in certain models, though the mechanistic basis for interaction is not fully established.
For researchers choosing between the blend and separate products: the blend fixes the ratio at 1:1 (5mg each), which may not match all research protocols. Separate products give independent dose control. The blend is convenient for studies where the fixed combination is appropriate or where exploring the combination effect is the primary interest.
Within the Tissue-Repair Cluster — How the Blend Differs
The BPC-157 + TB-500 blend sits alongside the two standalone research peptides in CertaPeptides' tissue-repair cluster: BPC-157 and TB-500. The primary distinction between buying the blend versus the two individual peptides is ratio control versus handling simplicity:
| Scenario | Blend (this product) | Separate products |
|---|---|---|
| Fixed ratio | 1:1 (5mg : 5mg per vial) | Researcher-defined ratio |
| Reconstitution events | One vial | Two vials |
| Dose-response experiments | Limited — both components vary together | Each peptide titrated independently |
| Isolated-pathway studies | Not suitable — both peptides always present | Single-peptide protocols possible |
| Appropriate when | Studying the combination effect; established 1:1 protocol; logistics matter | Mechanism isolation; dose-response; one peptide is the primary interest |
Researchers choosing between the blend and separate products frequently reference the BPC-157 vs TB-500 vs blend decision guide, the TB-500 vs BPC-157 comparison, and the broader research-peptide stacks overview.
Research Applications
Used in tissue repair and healing research, musculoskeletal injury models, GI mucosal biology, nitric oxide pathway studies, and combination peptide pharmacology. Also used to investigate whether BPC-157's established oral bioavailability extends to any systemic effects that parallel those seen with TB-500 in parenteral research models.
Specifications
| Parameter | Value |
|---|---|
| Component 1 | BPC-157 5mg (CAS 137525-51-0) |
| Component 2 | TB-500 5mg (Thymosin Beta-4 fragment) |
| Total per Vial | 10mg combined |
| Purity | ≥98% per component (supplier batch spec) |
| Format | Lyophilized powder, single-use vial |
| Storage | -20°C before reconstitution; 2-8°C after |
Storage
Store unreconstituted vials at -20°C. After reconstitution with bacteriostatic water, refrigerate at 2-8°C and use within 28 days. Avoid repeated freeze-thaw of reconstituted solution.
What is the research basis for combining BPC-157 and TB-500?
BPC-157 and TB-500 work through different but complementary pathways. BPC-157 modulates the nitric oxide system, promotes angiogenesis through VEGFR2 signaling, and shows strong GI mucosal protection. TB-500 regulates actin dynamics, promotes cell migration and proliferation, and has anti-inflammatory effects. Both have been studied in healing and repair contexts. The combination hypothesis is that addressing both vascular/mucosal protection (BPC-157 territory) and cellular motility required for tissue remodeling (TB-500 territory) may produce better outcomes than either alone, though this needs study-specific verification.
Why use the blend vs separate BPC-157 and TB-500 products?
The blend is convenient when a 1:1 ratio (5mg each) matches the research protocol and the goal is studying the combination effect. Separate products provide independent dose control -- essential when testing different ratios, conducting dose-response experiments, or when one peptide is the primary interest. For exploratory studies or established protocols using both peptides, the blend simplifies logistics.
How is this product reconstituted?
Reconstitute with bacteriostatic water (preservative helps with stability after opening) or sterile water for single-use protocols. The lyophilized cake should dissolve clear within a few minutes -- avoid vigorous shaking, which can denature peptides. For storage after reconstitution, keep at 2-8 degrees C and use within 28 days. Calculate volume based on the total peptide content (10mg) and your target concentration.
BPC-157 + TB-500 Blend is supplied for laboratory research use only. Not approved for human use. Handle in compliance with institutional biosafety guidelines.
Specification Summary
About BPC-157 + TB-500 Blend
BPC-157 + TB-500 is a blend combining two of the most widely researched tissue repair peptides. BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide with documented stability in gastric conditions and well-replicated effects on GI mucosal protection, tendon healing, and nitric oxide pathway modulation. TB-500 is the 17-amino acid LKKTET-containing fragment of thymosin beta-4, responsible for actin cytoskeleton regulation, cell migration, and anti-inflammatory signaling. Each vial contains 5mg BPC-157 and 5mg TB-500 (10mg total).
The rationale for combining them is mechanistic complementarity. BPC-157 primarily modulates the nitric oxide system, promotes angiogenesis through VEGFR2 signaling, and protects mucosal surfaces. TB-500 acts through actin dynamics and cell migration -- it promotes the cell movement needed for tissue remodeling and repair. Both have been studied in overlapping contexts (fibroblast proliferation in cited models, tendon repair, muscle injury), but through different enough mechanisms that combination research is scientifically justified. Some published studies have examined co-administration and found additive effects in certain models, though the mechanistic basis for interaction is not fully established.
For researchers choosing between the blend and separate products: the blend fixes the ratio at 1:1 (5mg each), which may not match all research protocols. Separate products give independent dose control. The blend is convenient for studies where the fixed combination is appropriate or where exploring the combination effect is the primary interest.
Within the Tissue-Repair Cluster — How the Blend Differs
The BPC-157 + TB-500 blend sits alongside the two standalone research peptides in CertaPeptides' tissue-repair cluster: BPC-157 and TB-500. The primary distinction between buying the blend versus the two individual peptides is ratio control versus handling simplicity:
| Scenario | Blend (this product) | Separate products |
|---|---|---|
| Fixed ratio | 1:1 (5mg : 5mg per vial) | Researcher-defined ratio |
| Reconstitution events | One vial | Two vials |
| Dose-response experiments | Limited — both components vary together | Each peptide titrated independently |
| Isolated-pathway studies | Not suitable — both peptides always present | Single-peptide protocols possible |
| Appropriate when | Studying the combination effect; established 1:1 protocol; logistics matter | Mechanism isolation; dose-response; one peptide is the primary interest |
Researchers choosing between the blend and separate products frequently reference the BPC-157 vs TB-500 vs blend decision guide, the TB-500 vs BPC-157 comparison, and the broader research-peptide stacks overview.
Research Applications
Used in tissue repair and healing research, musculoskeletal injury models, GI mucosal biology, nitric oxide pathway studies, and combination peptide pharmacology. Also used to investigate whether BPC-157's established oral bioavailability extends to any systemic effects that parallel those seen with TB-500 in parenteral research models.
Specifications
| Parameter | Value |
|---|---|
| Component 1 | BPC-157 5mg (CAS 137525-51-0) |
| Component 2 | TB-500 5mg (Thymosin Beta-4 fragment) |
| Total per Vial | 10mg combined |
| Purity | ≥98% per component (supplier batch spec) |
| Format | Lyophilized powder, single-use vial |
| Storage | -20°C before reconstitution; 2-8°C after |
Storage
Store unreconstituted vials at -20°C. After reconstitution with bacteriostatic water, refrigerate at 2-8°C and use within 28 days. Avoid repeated freeze-thaw of reconstituted solution.
What is the research basis for combining BPC-157 and TB-500?
BPC-157 and TB-500 work through different but complementary pathways. BPC-157 modulates the nitric oxide system, promotes angiogenesis through VEGFR2 signaling, and shows strong GI mucosal protection. TB-500 regulates actin dynamics, promotes cell migration and proliferation, and has anti-inflammatory effects. Both have been studied in healing and repair contexts. The combination hypothesis is that addressing both vascular/mucosal protection (BPC-157 territory) and cellular motility required for tissue remodeling (TB-500 territory) may produce better outcomes than either alone, though this needs study-specific verification.
Why use the blend vs separate BPC-157 and TB-500 products?
The blend is convenient when a 1:1 ratio (5mg each) matches the research protocol and the goal is studying the combination effect. Separate products provide independent dose control -- essential when testing different ratios, conducting dose-response experiments, or when one peptide is the primary interest. For exploratory studies or established protocols using both peptides, the blend simplifies logistics.
How is this product reconstituted?
Reconstitute with bacteriostatic water (preservative helps with stability after opening) or sterile water for single-use protocols. The lyophilized cake should dissolve clear within a few minutes -- avoid vigorous shaking, which can denature peptides. For storage after reconstitution, keep at 2-8 degrees C and use within 28 days. Calculate volume based on the total peptide content (10mg) and your target concentration.
BPC-157 + TB-500 Blend is supplied for laboratory research use only. Not approved for human use. Handle in compliance with institutional biosafety guidelines.
Related research reading
Objective comparisons and research guides covering this compound. Reference material for research use only.
Researcher Confidence
Why researchers choose CertaPeptides
Who actually tests this?
Selected lots are independently verified by Janoshik Analytical (Czech Republic) and published on the Janoshik public portal. Other lots ship with the supplier's batch specification. See /coa for the published wall.
View COAs →What if I get the wrong batch?
Every bottle label carries a lot number that maps to a specific Certificate of Analysis. If a batch fails spec, we don't ship it — full stop.
View COAs →Where does it ship from?
Romania (EU). We are CERTALAB SRL, CUI 54169956, VAT-registered. Sameday for Romania, GLS for most EU destinations, TCE Worldwide for the remaining cross-border EU and non-EU markets (UK, Switzerland, Iceland, Serbia). Delivery 1–15 business days depending on destination — exact window shown at checkout.
Shipping details →What if there's a problem?
You have a 14-day withdrawal right under OUG 34/2014 (Romanian/EU consumer law), with ANPC/ODR escalation available. Contact us at support@certapeptides.com.
Returns policy →Product Information
This product is intended for scientific research and development purposes only. It is a chemical substance that shall not be used as a drug, medicine, active substance, or ingredient in any product intended for human or animal consumption. Researchers must handle this compound in accordance with their institutional biosafety guidelines. Use only in properly equipped laboratory settings with appropriate personal protective equipment.
